| Host: |
Rabbit |
| Applications: |
WB/IF/ICC/ELISA |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. |
| Purification: |
Affinity purification |
| Concentration: |
Lot specific |
| Dilution Range: |
WB:1:500-1:2000IF/ICC:1:50-1:200ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
| Gene Symbol: |
C4BPA |
| Gene ID: |
722 |
| Uniprot ID: |
C4BPA_HUMAN |
| Immunogen Region: |
298-597 aa |
| Specificity: |
Recombinant fusion protein containing a sequence corresponding to amino acids 298-597 of human C4BPA (NP_000706.1). |
| Immunogen Sequence: |
SCINLPDIPHASWETYPRPT KEDVYVVGTVLRYRCHPGYK PTTDEPTTVICQKNLRWTPY QGCEALCCPEPKLNNGEITQ HRKSRPANHCVYFYGDEISF SCHETSRFSAICQGDGTWSP RTPSCGDICNFPPKIAHGHY KQSSSYSFFKEEIIYECDKG YILVGQAKLSCSYSHWSAPA PQCKALCRKPELVNGRLSVD KDQYVEPENVTIQCDSGYGV VGPQSITCSGNRTWYPEVP |
| Tissue Specificity | Chylomicrons in the plasma. |
| Function | Controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. Alpha chain binds C4b. It interacts also with anticoagulant protein S and with serum amyloid P component. |
| Protein Name | C4b-Binding Protein Alpha ChainC4bpProline-Rich ProteinPrp |
| Database Links | Reactome: R-HSA-977606 |
| Cellular Localisation | Secreted |
| Alternative Antibody Names | Anti-C4b-Binding Protein Alpha Chain antibodyAnti-C4bp antibodyAnti-Proline-Rich Protein antibodyAnti-Prp antibodyAnti-C4BPA antibodyAnti-C4BP antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
